4.7 Article

ASK1 inhibitors are potential pan-antiviral drugs, which dampen replication of diverse viruses including SARS-CoV2

期刊

ANTIVIRAL RESEARCH
卷 220, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.antiviral.2023.105736

关键词

Antiviral; SARS-CoV-2; ASK1; Vesicular stomatitis virus; Herpes simplex virus; Selonsertib

向作者/读者索取更多资源

The study found that virus infection activates ASK1-related pathways, and the ASK1 inhibitor Selonsertib significantly reduces the replication of various viruses in human cell lines. However, differential effects of Selonsertib were observed in in vitro and in vivo hamster models, suggesting caution in predicting clinical and therapeutic outcomes in humans using rodent models.
Apoptosis signal-regulating kinase 1 (ASK1)/MAP3K5 is a stress response kinase that is activated by various stimuli. It is known as an upstream activator of p38- Mitogen-activated protein kinase (p38MAPK) and c-Jun Nterminal kinase (JNK) that are reactive oxygen species (ROS)-induced kinases. Accumulating evidence show that ROS accumulate in virus-infected cells. Here, we investigated the relationship between viruses and ASK1/ p38MAPK or ASK1/JNK pathways. Our findings suggest that virus infection activates ASK1 related pathways. In parallel, ASK1 inhibition led to a remarkable reduction in the replication of a broad range of viruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccinia virus (VV), vesicular stomatitis virus (VSV), Herpes Simplex Virus (HSV), and Human Immunodeficiency virus (HIV) in different human cell lines. Our work demonstrates the potential therapeutic use of Selonsertib, an ASK1 inhibitor, as a pan-antiviral drug in humans. Surprisingly, we observed differential effects of Selonsertib in in vitro and in vivo hamster models, suggesting caution in using rodent models to predict clinical and therapeutic outcomes in humans.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据